Mission

Valens Therapeutics is a small privately held pharmaceutical company focusing on the development of the next generation of novel therapeutics to address important unmet medical needs. They include therapeutics to treat diseases caused by abnormal angiogenesis, and diseases caused by infectious pathogens. The company's proprietary molecules target human proteins involved in abnormal vascular growth, pathological conditions of the eye, cancer, tumor growth, metastasis, and other disease conditions, and proteins from infectious pathogens including viruses and bacteria.

The company’s platform technology comprises a class of compounds with enhanced physicochemical properties, highly stable, resistant to degradation by enzymes and stable folding structures that could potentially be developed into drug candidates against several target areas including ophthalmology, oncology, neurology, inflammation, and infectious diseases. The technology consists of conjugating several different proprietary molecules to a non-toxic, water soluble, safe, non-immunogenic and biocompatible polymer to create novel next-generation multi-targeted therapeutics for the treatment of a variety of human diseases, for which there are no effective treatment.drugs. This technology is early stage but our approach to create novel compounds could potentially bring effective new therapies to patients with unmet medical needs. 

In the area of ophthalmology, the company is developing a lead product with unique characteristics not observed in the available ocular therapies, for the treatment of ocular pathologies. Neovascularization in the eye causes a variety of diseases including macular degeneration, choroidal neovascularization, diabetic retinopathy and other eye pathologies. These ophthalmologic disorders offer major opportunities for improved therapies.

In the area of oncology, the company is developing a novel multi-targeted therapeutic for the treatment of pancreatic cancer; one of the deadliest human cancers for which there is no cure and no effective treatment drugs.

In the area of infectious diseases, the company is developing a novel multi-targeted anti-HIV therapeutic vaccine for the treatment and prevention of HIV/AIDS. The lack of effective anti-retrovirals and a prophylactic vaccine for HIV offer major opportunities to develop novel inhibitors for HIV and therapeutic vaccines.

In the area of neurology, the company is developing a therapy for Hungtington's disease, a desvastating disease of the brain and the body. Some molecules have potential for HD and other brain diseases.

Valens’ platform technology comprises molecules capable of modifying disease state cell characteristics. The molecules directly impact on the cell by targeting the intracellular interactions between proteins, and by disrupting several biological interactions important for cell function and survival. In the case of pathogens, the molecules impact on the fusion of viral and cell-membrane proteins during viral infection and entry into the cell. The technology and proprietary molecules have also potential applications in diseases caused by pathogenic bacteria, fungi and parasites.

The company is building value through its owned intellectual property portfolio of pending patents.